Newsletter | December 17, 2025

12.17.25 -- Top 10 Of 2025

BEST OF FROM THE EDITOR

1.

The FDA 483 Heard Round The World

2.

Will It Not Die? The BIOSECURE Act Back With Iterations

3.

CDMOs Should Stop Stringing Biotechs Along

4.

Did Trump Just Create An Antibiotic Supply Chain In The U.S.?

5.

A (Partial) Vindication For Wuxi AppTec … And Global Outsourcing

6.

Lilly's Kinsale Facility Provides A Benchmark For Your CDMO Selection

7.

As Billions Of Dollars Pour In, Do CDMO Valuations Matter?

8.

Tech Transfer 2025 – A High-Stakes Game Of Trust

9.

Paying For Lots Of Formulation Work At Your CDMO

10.

The 15% Tariff: A Modest Jolt Or Deeper Disruption?

BEST OF INDUSTRY INSIGHTS

1.

Creating A Compliant And Scalable CGT Logistics Launch Plan

2.

Revolutionizing Viral Vector Production With Intensified Cell Culture

3.

How-To Master Tech Transfer: Strategies To Sidestep Common Pitfalls

4.

De-Risking Cell Therapy Development: 4 Keys To A Streamlined IND Path

5.

Future-Proofing Life Sciences Manufacturing: 2025 CDMO Trends

6.

Phase-Appropriate Approaches To Manufacturing And Testing

7.

Emerging Vaccine Technologies

8.

Developing Scalable, Global Solutions For Cell & Gene Manufacturing

9.

Put Your AAV On The Fast-Track To The Clinic

10.

4 Key Autologous Manufacturing Challenges (Plus How To Solve Them)

BEST OF SOLUTIONS

1.

Advanced iPSC Workflows: Accelerating Cell Therapy Development

2.

Pharmaceutical Change Control Software

3.

Groundbreaking Cryogenic Freezer Technology

4.

Advancing Vaccines From Preclinical Development To Commercial Supply

5.

Future-Ready Development

6.

RNA Therapies

7.

Capabilities Update January 2025: Cell & Gene Therapy

8.

Quality GMP-Grade iPSC And Knockin-Ready TARGATT™ iPSC

9.

Allogeneic CAR-T Cells

10.

Quality Risk Management Software

Connect With Outsourced Pharma: